PolyPid Ltd. (PYPD)

NCM – Цена в реальном времени. Валюта: USD

4.75

+0.18 (3.94%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

4.92

+0.17 (3.58%)

После закрытия: Jun 26, 2026, 7:14 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

PolyPid Ltd. (PYPD)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

PolyPid Ltd. (PYPD)

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference

PolyPid Q1 Earnings Call Highlights

PolyPid Ltd. (PYPD) Q1 2026 Earnings Call Transcript

PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results

PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026

PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting

Видео

No Data

Пресс-релизы

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀'s New Drug Application

Search stocks

PolyPid Ltd. (PYPD)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

PolyPid Ltd. (PYPD)

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference

PolyPid Q1 Earnings Call Highlights

PolyPid Ltd. (PYPD) Q1 2026 Earnings Call Transcript

PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results

PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026

PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting

Видео

No Data

Пресс-релизы

PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀

PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results

PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA

PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀'s New Drug Application